Aegerion blew away sales estimates for the second quarter by more than 50%, and so investors initially rewarded the stock with gains of nearly 24% in early Tuesday trading. Shares soared past the $95 level at one point, setting an all-time record. But then that courage dissipated. The stock still ended trading on a positive note but had settled back to $82.79.

On Wednesday, investors were emboldened again by sales of the cholesterol drug Juxtapid, which was approved for sale in the U.S. in December, and Aegerion shares ended the day with a gain of more than 10% at $91.59. Several analysts also upped their price targets on the stock, including Salveen Richter, who went to $110 from $90.

“[We] expect continued solid launch execution of [Juxtapid], with European Union approval [around] Aug. 6 to serve as the next catalyst,” she wrote in a note to clients.

The home-health and hospice company’s adjusted earnings of 17 cents a share came in well ahead of the 10 cents predicted by FactSet’s poll of analysts. That came despite 9 cents of negative impact attributed to the federal government’s sequestration.

Story Conversation

About Health Exchange

Health Exchange guides investors to the crucial market intelligence they need to keep up with the health care industry, which makes up one-sixth of the U.S. economy. Anchored by Russ Britt, Health Exchange is the essential site for those looking for the most important news, data and analysis on the sector. You can reach Russ at Rbritt@marketwatch.com.